|
Real-time Estimate
Cboe Europe
19:35:27 13/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 1,781.25 GBX | +0.58% |
|
+1.02% | -2.25% |
| 05:25pm | Major drugmakers turn to China for licensing deals | RE |
| 10-10 | Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs | RE |
| Market Cap | 70.96B 93.75B 83.93B 78.24B 134B 8,962B 135B 940B 368B 4,625B 352B 344B 14,882B | P/E 2026 * |
13.5x | P/E 2027 * | 11.1x |
|---|---|---|---|---|---|
| Enterprise Value | 92.14B 122B 109B 102B 174B 11,637B 175B 1,221B 478B 6,005B 457B 447B 19,324B | EV / Sales 2026 * |
2.72x | EV / Sales 2027 * | 2.51x |
| Free-Float |
92.75% | Yield 2026 * |
3.92% | Yield 2027 * | 4.22% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
OTC Markets
| GLAXF | Delayed | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Deutsche Boerse AG
| GS71 | Delayed | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
Börse Stuttgart
| GS71 | Delayed |
Last Transcript: GSK plc
| 1 day | +0.58% | ||
| 1 week | +1.02% | ||
| Current month | -2.65% | ||
| 1 month | -3.83% | ||
| 3 months | -8.70% | ||
| 6 months | -17.81% | ||
| Current year | -2.25% |
| 1 week | 1,735.5 |  | 1,806.5 |
| 1 month | 1,735.5 | | 1,917 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,592 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
James Ford
CMP | Compliance Officer | - | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 67 | 01/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 22/9/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 18/9/26 | Buy | Director | 768 | 0.0000% | ||
| 18/9/26 | Buy | Director | 1,734 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.58% | +1.02% | +9.59% | +18.11% | 93.75B | |
| +0.28% | +3.46% | +41.89% | +93.71% | 1,054B | |
| +0.88% | +4.27% | +38.28% | +68.70% | 636B | |
| +1.68% | +5.78% | +21.96% | +89.56% | 497B | |
| -0.10% | +4.24% | +69.15% | +40.41% | 359B | |
| +1.13% | +4.23% | +25.68% | +42.95% | 345B | |
| +1.07% | +3.53% | +16.10% | +38.62% | 273B | |
| +1.23% | +2.16% | -3.99% | +11.32% | 246B | |
| +0.65% | +3.62% | +43.93% | +46.50% | 226B | |
| -0.49% | +4.01% | +28.38% | +95.97% | 187B | |
| Average | +0.38% | +2.90% | +29.09% | +54.59% | 391.6B | |
| Weighted average by Cap. | +0.22% | +3.13% | +33.86% | +66.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.92B 44.81B 40.12B 37.4B 63.98B 4,284B 64.38B 449B 176B 2,211B 168B 165B 7,114B | 35.51B 46.92B 42B 39.15B 66.98B 4,485B 67.4B 471B 184B 2,314B 176B 172B 7,448B |
| Net income | 5.32B 7.03B 6.29B 5.87B 10.03B 672B 10.1B 70.49B 27.59B 347B 26.4B 25.82B 1,116B | 6.33B 8.36B 7.48B 6.97B 11.93B 799B 12B 83.81B 32.81B 412B 31.39B 30.7B 1,327B |
| Net Debt | 21.18B 27.98B 25.05B 23.35B 39.95B 2,675B 40.2B 281B 110B 1,380B 105B 103B 4,442B | 18.28B 24.15B 21.62B 20.16B 34.48B 2,309B 34.7B 242B 94.82B 1,191B 90.73B 88.72B 3,834B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/10/26 | GBX 1,783.50 | +0.71% | 545,151 |
| 12/10/26 | GBX 1,771.00 | +1.20% | 3,352,492 |
| 09/10/26 | GBX 1,750.00 | +0.84% | 6,931,381 |
| 08/10/26 | GBX 1,735.50 | -3.07% | 16,331,288 |
| 07/10/26 | GBX 1,790.50 | +1.42% | 5,172,881 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
